Melinta Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update
09 mai 2019 16h00 HE
|
Melinta Therapeutics
~ Revenue of $14.1 million, Including Net Product Sales of $11.8 million, for the First Quarter 2019 ~ ~ Reduction of Operating Expenses of 34 Percent, or $19.8 million, Year-Over-Year ~ ~...
Melinta Therapeutics to Present at Making a Difference in Infectious Diseases (MAD-ID) 2019 Annual Meeting
07 mai 2019 07h30 HE
|
Melinta Therapeutics
MORRISTOWN, N.J., May 07, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to...
Arch Biopartners Announces Issuance of U.S. Patent for Its Novel Antibacterial Drug AB569, Designed to Target Chronic Infection and Antibiotic Resistance
27 mars 2018 09h08 HE
|
Arch Biopartners
TORONTO, March 27, 2018 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (Arch or the Company) (TSX Venture:ARCH) (OTCBB:ACHFF), announced today that the U.S. Patent and Trademark Office has issued U.S....
Arch Biopartners Arranges Convertible Note Financing
08 févr. 2018 07h30 HE
|
Arch Biopartners
TORONTO, Feb. 08, 2018 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture:ARCH) (OTCBB:ACHFF), announced it has arranged a non-brokered, unsecured convertible note...
Melinta Therapeutics’ Topical Radezolid Well Tolerated in Phase 1 Study for Treatment of Acne
10 oct. 2017 08h00 HE
|
Melinta Therapeutics
NEW HAVEN, Conn., Oct. 10, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial...
New Elsevier Book Addresses Challenges of Microbial Drug Resistance
13 mars 2017 14h00 HE
|
Elsevier, Inc.
CAMBRIDGE, MA--(Marketwired - March 13, 2017) - Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced the publication of...
ContraFect Announces Presentation of Data at ASM Microbe 2016
08 juin 2016 07h00 HE
|
ContraFect Corporation
YONKERS, NY--(Marketwired - June 08, 2016) - ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW), a biotechnology company focused on the discovery and development of protein and antibody...
ContraFect to Present at Jefferies 2016 Healthcare Conference
01 juin 2016 07h00 HE
|
ContraFect Corporation
YONKERS, NY--(Marketwired - June 01, 2016) -
ContraFect Corporation
(NASDAQ: CFRX)
(NASDAQ: CFRXW), a biotechnology company focused on the discovery and development of...
Melinta Therapeutics Raises $70 Million to Support Delafloxacin NDA and Selection of Multi-Drug Resistant Gram-Negative Candidates from RX-04 Platform
10 févr. 2014 07h30 HE
|
Melinta Therapeutics
NEW HAVEN, Conn, Feb. 10, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today
announced the closing of a $70 Million Series 3 equity
financing. Current investor, Vatera Healthcare Partners,...